Clinical trial · Interventional
Exemestane in Advanced and Recurrent Endometrial Carcinoma
Phase 2 Study of Exemestane in Advanced and Recurrent Endometrial Carcinoma
NCT01965080CI-TRIAL-00012417completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A phase II study of Exemestane in Advanced or recurrent endometrial carcinoma Hypothesis: Treatment With Exemestane can give a response rate of at least 30%
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Endometrial Cancer | Malignant Endometrial Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Exemestane | Drug | Exemestane | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Exemestane
- description
- Exemestane 25 mg daily
- interventionNames
- Drug: Exemestane
Primary outcomes (1)
- measure
- Response rate
- timeFrame
- 6 months
- description
- Objective response rate within 6 months of treatment
Secondary outcomes (1)
- measure
- Progression free survival
- timeFrame
- 2 years
- description
- Special attention to progression status at 6 months
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Advanced or recurrent endometrial cancer not considered for treatment modalities apart from hormonal treatment * Endometrioid histology * Age above 18 years * Post menopausal status * Performance status 0-2 * Informed consent Exclusion Criteria: * Congestive heart disease grade III.IV * History of thromboembolic signs * Other primary hormonal therapy * Patients With symptomatic brain metastasis * Severe hepatic or renal impairment * Pregnancy, lactation or child bearing potential without adequate contraception
References
Publications (1)
- DERIVEDLindemann K, Malander S, Christensen RD, Mirza MR, Kristensen GB, Aavall-Lundqvist E, Vergote I, Rosenberg P, Boman K, Nordstrom B. Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO). BMC Cancer. 2014 Feb 5;14:68. doi: 10.1186/1471-2407-14-68. PMID 24498853